Literature DB >> 9521151

Kinetics of local and systemic immune responses to an oral cholera vaccine given alone or together with acetylcysteine.

J Kilhamn1, M Jertborn, A M Svennerholm.   

Abstract

The possibility that a mucolytic drug, i.e., acetylcysteine, given orally may enhance the gut mucosal or systemic immune response to an oral B-subunit-whole-cell (B-WC) cholera vaccine was evaluated for 40 adult Swedish volunteers, and the kinetics of the immune responses were monitored for responding volunteers. Two doses of vaccine induced similar frequencies of immunoglobulin A (IgA) and IgG antitoxin responses (80 to 90%) and vibriocidal titer increases (60 to 65%) in serum irrespective of whether the vaccine was given alone or together with 2 g of acetylcysteine. In feces the frequencies of IgA antitoxin (67%) and antibacterial (33 to 40%) antibody responses were also comparable in the two immunization groups. Six months after vaccination, IgA and IgG antitoxin as well as vibriocidal antibody titer increases in serum could still be detected in approximately 80% of initially responding vaccinees. Significantly elevated fecal antitoxin and antibacterial IgA antibody levels were found in, respectively, 50 and 43% of those volunteers who initially had responded to the vaccine. Determination of IgA antibodies in feces does not seem to offer any advantages compared to determination in serum for assessment of immune responses after immunization with inactivated cholera vaccine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521151      PMCID: PMC121366          DOI: 10.1128/CDLI.5.2.247-250.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  28 in total

1.  PASSIVE SERUM PROTECTION OF THE INFANT RABBIT AGAINST EXPERIMENTAL CHOLERA.

Authors:  O R MCINTYRE; J C FEELEY
Journal:  J Infect Dis       Date:  1964-12       Impact factor: 5.226

2.  Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine.

Authors:  B Olsson; M Johansson; J Gabrielsson; P Bolme
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Five-year immunologic memory in Swedish volunteers after oral cholera vaccination.

Authors:  M Jertborn; A M Svennerholm; J Holmgren
Journal:  J Infect Dis       Date:  1988-02       Impact factor: 5.226

4.  Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole-cell cholera vaccine.

Authors:  J D Clemens; M Jertborn; D Sack; B Stanton; J Holmgren; M R Khan; S Huda
Journal:  J Infect Dis       Date:  1986-07       Impact factor: 5.226

5.  Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease.

Authors:  M Jertborn; A M Svennerholm; J Holmgren
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

6.  Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.

Authors:  A M Svennerholm; M Jertborn; L Gothefors; A M Karim; D A Sack; J Holmgren
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

7.  Safety and drug interactions of oral acetylcysteine related to utilization data.

Authors:  V Ferrari
Journal:  Eur J Respir Dis Suppl       Date:  1980

8.  Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens.

Authors:  N Lycke; J Holmgren
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

9.  A method of obtaining, processing, and analyzing human intestinal secretions for antibody content.

Authors:  M M Gaspari; P T Brennan; S M Solomon; C O Elson
Journal:  J Immunol Methods       Date:  1988-05-25       Impact factor: 2.303

10.  Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.

Authors:  G Boman; U Bäcker; S Larsson; B Melander; L Wåhlander
Journal:  Eur J Respir Dis       Date:  1983-08
View more
  5 in total

1.  Immune responses in ileostomy fluid and serum after oral cholera vaccination of patients colectomized because of ulcerative colitis.

Authors:  J Kilhamn; H Brevinge; A M Svennerholm; M Jertborn
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

2.  Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans.

Authors:  A Rudin; E L Johansson; C Bergquist; J Holmgren
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

3.  Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans.

Authors:  Lotta Wassen; Marianne Jertborn
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

4.  Intestinal and systemic immune responses to an oral cholera toxoid B subunit whole-cell vaccine administered during zinc supplementation.

Authors:  Tom H Karlsen; Halvor Sommerfelt; Skjalg Klomstad; Per Kragh Andersen; Tor A Strand; Rune J Ulvik; Christina Ahrén; Harleen M S Grewal
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

5.  Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial.

Authors:  Leesun Kim; David Liebowitz; Karen Lin; Kassandra Kasparek; Marcela F Pasetti; Shaily J Garg; Keith Gottlieb; George Trager; Sean N Tucker
Journal:  JCI Insight       Date:  2018-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.